TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03599284
Drug: Vicagrel 7.5mg
DrugBank: Vicagrel (DB16349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
Study: NCT05213832
Drug: Isoflurane Inhal Soln
Normalized name: isoflurane Inhalation Solution
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of isofluorane in patients with severe SAH
Study: NCT01648465
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
Study: NCT03599284
Drug: Clopidogrel 75mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
Study: NCT02543879
Drug: FT-1101
Normalized name: FT-1101
DrugBank: FT-1101 (DB17553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
Study: NCT02543879
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine will be administered per site's standard of care
Study: NCT03973775
Drug: Permethrin Cream 5%
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.
Study: NCT00688116
Drug: STA 9090 (ganetespib)
Normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., \[Monday, Thursday\] or \[Tuesday, Friday\]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.
Study: NCT01623102
Drug: cisplatin and gemcitabine combination with Bevacizumab
Normalized name: Cisplatin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.
Study: NCT01623102
Drug: Gemcitabine combined with cisplatin chemotherapy
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.
Study: NCT01657903
Drug: Sodium Fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toothpaste containing 1450 ppm F - EU level as NaF.
Study: NCT00627393
Drug: G-CSF/dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
Study: NCT03337308
Drug: Bempedoic Acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: bempedoic acid 180 mg tablet
Study: NCT03337308
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ezetimibe 10 mg overencapsulated tablet
Study: NCT01794429
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneum injection of exenatide once-weekly for 3 months
Study: NCT03746769
Drug: Gastrin 17
Normalized name: Antigastrin 17
DrugBank: G17DT Immunogen (DB04914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.~Also, anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.
Study: NCT01657903
Drug: Potassium nitrate
Normalized name: Potassium Nitrate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All study treatments contain 5% w/w KNO3.
Study: NCT02976194
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
Study: NCT00090246
Drug: MK0869, aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00090246
Drug: Comparator: ondansetron IV
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01359488
Drug: VRS-317
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VRS-317 Single Dose
Study: NCT01359488
Drug: VRS-317
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VRS-317 Single dose
Study: NCT04479358
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 40mg
Study: NCT04479358
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 120mg
Study: NCT00670423
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus as a continuous IV infusion will begin on day -3. (Levels will be monitored at least every 3 days to target 5-10 ng/mL)
Study: NCT00670423
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus oral loading dose on day -3, followed by oral daily dose. (Levels will be monitored at least every 3 days to target 3-12 ng/mL)
Study: NCT00670423
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously on day 0 (a minimum of 6 hours post-infusion of PBSC), and on day +3. The following dose levels will be used:~Cohort 1 (3-6 pts): 1 mg/m2 on days 0 and +3~Cohort 2 (3-6 pts): 1.3 mg/m2 on days 0 and +3~Cohort 3 (3-10 pts): 1.6 mg/m2 on days 0 and +3
Study: NCT01131975
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine Tablets (chewable, dispersible), 25 mg
Study: NCT03821935
Drug: Livmoniplimab
Normalized name: Livmoniplimab
DrugBank: Livmoniplimab (DB18939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid for intravenous infusion.
Study: NCT03821935
Drug: Budigalimab
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized powder for solution for intravenous infusion.
Study: NCT00374140
Drug: RAD001 (everolimus)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
Study: NCT03471260
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or SC
Study: NCT03471260
Drug: Ivosidenib
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03471260
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03611179
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications.~In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h.~Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)
Study: NCT02338986
Drug: Plasma
Normalized name: Plasma
DrugBank: Plasma protein fraction (human) (DB13968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma
Study: NCT00808184
Drug: CPT-11, Raltegravir (Isentress®), Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03957551
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib is an oral small molecule potent inhibitor of pro-invasive receptor tyrosine kinases (RTKs).~Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day, in combination with pembrolizumab. The drug is taken continuously for 21 days or 3 weeks. This period of time is defined as one treatment cycle.
Study: NCT03957551
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a humanized antibody which will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks in combination with cabozantinib.
Study: NCT01914042
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01914042
Drug: Milnacipran
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00099606
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
Study: NCT00333242
Drug: dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dextromethorphan PO titrated to 480 mg/day x 5 weeks
Study: NCT00460499
Drug: A IV Insulin drip
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
Study: NCT00460499
Drug: B Low Dose GIK
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
Study: NCT00460499
Drug: C High Dose GIK
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
Study: NCT00045006
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02286622
Drug: Deflazacort
Normalized name: Deflazacort
DrugBank: Deflazacort (DB11921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone
Study: NCT00236223
Drug: Gabapentin + dexamethasone + ketamine
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg
Study: NCT04094285
Drug: STICKSTOFF
Normalized name: Stickstoffmonoxid
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: STICKSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~88% with 12% oxygen, breathing for 30 minutes
Study: NCT02129192
Drug: Amlodipine 5mg capsule
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5mg capsule
Study: NCT04381832
Drug: Etrumadenant
Normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrumadenant is an A2aR and A2bR antagonist
Study: NCT04381832
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimberelimab is an anti-PD-1 antibody
Study: NCT04381832
Drug: Quemliclustat
Normalized name: Quemliclustat
DrugBank: Quemliclustat (DB19160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.
Study: NCT04381832
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide is an androgen receptor inhibitor
Study: NCT04381832
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel is type of chemotherapy
Study: NCT04381832
Drug: SG
Normalized name: GSSG
DrugBank: Glutathione disulfide (DB03310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacituzumab govitecan is an antibody-drug conjugate
Study: NCT01231620
Drug: Zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
Study: NCT01231620
Drug: Placebo to match zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
Study: NCT01231620
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir will be provided as over-encapsulated 75 mg capsules.
Study: NCT06390852
Drug: Larotrectinib
Normalized name: Larotrectinib
DrugBank: Larotrectinib (DB14723)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01231620
Drug: Placebo to match oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
Study: NCT00005800
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04678895
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule with doses of 1.5mg, 3mg, and 4.5 mg to allow for drug titration. Capsules of different dosages will be indistinguishable to allow for maintenance of blinding.
Study: NCT01018069
Drug: AEG35156
Normalized name: AEG35156
DrugBank: AEG35156 (DB06184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
Study: NCT04435288
Drug: week 24
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the week 24 timepoint, there are 3 possible scenario's:~1. In patients that do not reach a state of clinical remission at week 24, blinded study medication will be interrupted and all patients will start open-label SC golimumab for an additional 36 weeks (up to max. week 60).~2. In patients that achieve sustained clinical remission at week 24, defined as absence of clinical arthritis, enthesitis and dactylitis at both week 12 and week 24, all study medication will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B.~3. In patients that reach a state of clinical remission at week 24, but that did not yet reach this status at week 12, blinded study medication will be continued without any change in the treatment schedule for another 12 weeks.
Study: NCT04435288
Drug: week 36
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At week 36, patients that have continued the blinded study medication, will be re-assessed regarding sustained clinical remission (at week 24 and 36): if yes, all study medication will again be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. If no, these patients will start open-label SC golimumab for an additional 24 weeks (up to max. week 60).~If patients were in the open-label golimumab treatment arm, effectiveness of the treatment will be assessed by using the PASSI-question. Inadequate responders will be discontinued from the study and will be treated with standard-of-care medication at the discretion of their treating rheumatologist, whereas patients with an acceptable improvement in signs and symptoms will continue with the same (open-label) medication schedule.
Study: NCT04435288
Drug: Week 48
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At week 48, all patients still remaining in SPARTACUS Phase A will have been treated with open-label golimumab (for a minimum of 12 weeks, but potentially up to 48 weeks). In patients reaching at this timepoint sustained clinical remission (at week 36 and 48), golimumab will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. For the other patients there are 3 possible scenarios:~1. If clinical remission for the first time at week 48, continuation without any change in the treatment schedule for another 12 weeks.~2. If an inadequate response (based on the PASSI-question), discontinuation from the study and standard-of-care medication~3. If an acceptable improvement (but no clinical remission), continuation open-label golimumab for an additional 12 weeks, with open-label methotrexate (unless contra-indicated) to fulfil Belgian reimbursement criteria for TNFi.
Study: NCT00347685
Drug: tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01314885
Drug: PF-03715455
Normalized name: PF-03715455
DrugBank: PF-03715455 (DB12138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg, Inhaled, single dose
Study: NCT01314885
Drug: PH-797804
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg, Oral, single dose
Study: NCT01314885
Drug: Placebo for PF-03715455
Normalized name: PF-03715455
DrugBank: PF-03715455 (DB12138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, inhaled, Placebo for PF-03715455
Study: NCT01314885
Drug: Placebo for PH-797804
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose, Oral, Placebo for PH-797804
Study: NCT00495274
Drug: Formulation C
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.
Study: NCT00495274
Drug: Formulation E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.
Study: NCT00495274
Drug: Formulation F
Normalized name: Yellow fever vaccine live - alternative formulation for vaccine shortage
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.
Study: NCT02364362
Drug: famitinib L + docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: famitinib 15mg qd + docetaxel 60 mg/m\^2
Study: NCT02364362
Drug: famitinib M + docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: famitinib 20mg qd + docetaxel 60 mg/m\^2
Study: NCT02364362
Drug: famitinib H + docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: famitinib 25mg qd + docetaxel 60 mg/m\^2
Study: NCT00412360
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
Study: NCT00412360
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
Study: NCT00412360
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF will be given at a dose of 1 gram IV q 8 hours if \> 50 kg or 15 mg/kg IV q 8 hours if \< 50 kg beginning the morning of Day -3.
Study: NCT04539444
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Tislelizumab 200mg/dose every 3 weeks.
Study: NCT01594424
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180
Study: NCT01594424
Drug: Intravenous Immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All HS who meet criteria for desensitization will receive IVIG 10% (2.0 g/kg \[maximum 140 g per dose\] on days 1 and 30).
Study: NCT01450566
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of lidocaine